The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity

Targeting the p53-MDM2 pathway to reactivate tumor p53 is a chemotherapeutic approach. However, the involvement of this pathway in CD8(+) T cell-mediated antitumor immunity is unknown. Here, we report that mice with MDM2 deficiency in T cells exhibit accelerated tumor progression and a decrease in tumor-infiltrating CD8(+) T cell survival and function. Mechanistically, MDM2 competes with c-Cbl for STAT5 binding, reduces c-Cbl-mediated STAT5 degradation and enhances STAT5 stability in tumor-infiltrating CD8(+) T cells. Targeting the p53-MDM2 interaction with a pharmacological agent, APG-115, augmented MDM2 in T cells, thereby stabilizing STAT5, boosting T cell immunity and synergizing with cancer immunotherapy. Unexpectedly, these effects of APG-115 were dependent on p53 and MDM2 in T cells. Clinically, MDM2 abundance correlated with T cell function and interferon-gamma signature in patients with cancer. Thus, the p53-MDM2 pathway controls T cell immunity, and targeting this pathway may treat patients with cancer regardless of tumor p53 status. The E3 ubiquitin ligase MDM2 inhibits the tumor suppressor p53 and is an important therapeutic target. Zou and colleagues demonstrate that MDM2 also has a T cell-intrinsic role that supports antitumor responses.

Automated summary

The E3 ubiquitin ligase MDM2, known for inhibiting the tumor suppressor p53, also plays a T cell-intrinsic role that supports antitumor responses. Targeting the p53-MDM2 pathway with APG-115 enhances T cell immunity and synergizes with cancer immunotherapy, with effects dependent on p53 and MDM2 in T cells. This highlights a potential therapeutic strategy for treating cancer patients, regardless of tumor p53 status.